Noncytotoxic differentiation treatment of renal cell cancer | ||
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Cleveland Clinic | |
| dc.conicet.organizacion | Cleveland Clinic | |
| dc.conicet.organizacion | Cleveland Clinic | |
| dc.conicet.organizacion | Cleveland Clinic | |
| dc.conicet.organizacion | Cleveland Clinic | |
| dc.conicet.organizacion | Cleveland Clinic | |
| dc.conicet.organizacion | Cleveland Clinic | |
| dc.conicet.organizacion | Cleveland Clinic | |
| dc.contributor.author | Negrotto, Soledad | |
| dc.contributor.author | Hu, Zhenbo | |
| dc.contributor.author | Alcazar, Oscar | |
| dc.contributor.author | Ng, Kwok Peng | |
| dc.contributor.author | Triozzi, Pierre | |
| dc.contributor.author | Lindner, Daniel | |
| dc.contributor.author | Rini, Brian | |
| dc.contributor.author | Saunthararajah, Yogen | |
| dc.date.issued | 2011-02 | |
| dc.description.abstract | Current drug therapy for metastatic renal cell cancer (RCC) results in temporary disease control but not cure, necessitating continued investigation into alternative mechanistic approaches. Drugs that inhibit chromatin-modifying enzymes involved in transcription repression (chromatin-relaxing drugs) could have a role, by inducing apoptosis and/or through differentiation pathways. At low doses, the cytosine analogue decitabine (DAC) can be used to deplete DNA methyl-transferase 1 (DNMT1), modify chromatin, and alter differentiation without causing apoptosis (cytotoxicity). Noncytotoxic regimens of DAC were evaluated for in vitro and in vivo efficacy against RCC cell lines, including a p53-mutated RCC cell line developed from a patient with treatment-refractory metastatic RCC. The cell division - permissive mechanism of action - absence of early apoptosis or DNA damage, increase in expression of HNF4α (hepatocyte nuclear factor 4a), a key driver associated with the mesenchymal to epithelial transition, decrease in mesenchymal marker expression, increase in epithelial marker expression, and late increase in cyclin-dependent kinase inhibitor CDKN1B (p27) protein - was consistent with differentiation-mediated cell-cycle exit. In vivo blood counts and animal weights were consistent with minimal toxicity of therapy. The distinctive mechanism of action of a dose and schedule of DAC designed for noncytotoxic depletion of DNMT1 suggests a potential role in treating RCC. ©2011 AACR. | es |
| dc.description.fil | Fil: Negrotto, Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Cleveland Clinic; Estados Unidos | |
| dc.description.fil | Fil: Hu, Zhenbo. Cleveland Clinic; Estados Unidos | |
| dc.description.fil | Fil: Alcazar, Oscar. Cleveland Clinic; Estados Unidos | |
| dc.description.fil | Fil: Ng, Kwok Peng. Cleveland Clinic; Estados Unidos | |
| dc.description.fil | Fil: Triozzi, Pierre. Cleveland Clinic; Estados Unidos | |
| dc.description.fil | Fil: Lindner, Daniel. Cleveland Clinic; Estados Unidos | |
| dc.description.fil | Fil: Rini, Brian. Cleveland Clinic; Estados Unidos | |
| dc.description.fil | Fil: Saunthararajah, Yogen. Cleveland Clinic; Estados Unidos | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Negrotto, Soledad; Hu, Zhenbo; Alcazar, Oscar; Ng, Kwok Peng; Triozzi, Pierre; et al.; Noncytotoxic differentiation treatment of renal cell cancer; American Association for Cancer Research; Cancer Research; 71; 4; 2-2011; 1431-1441 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 0008-5472 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/52945 | |
| dc.journal.ciudad | Philadelphia | es |
| dc.journal.number | 4 | es |
| dc.journal.pagination | 1431-1441 | es |
| dc.journal.pais | Estados Unidos | es |
| dc.journal.title | Cancer Research | es |
| dc.journal.volume | 71 | es |
| dc.language.iso | eng | es |
| dc.publisher | American Association for Cancer Research | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/https://dx.doi.org/10.1158/0008-5472.CAN-10-2422 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/http://cancerres.aacrjournals.org/content/71/4/1431 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | Decitabine | es |
| dc.subject | Differentiation | es |
| dc.subject | Renal Carcinoma | es |
| dc.subject | Cancer Treatment | es |
| dc.subject.classification | Inmunología | es |
| dc.subject.classification | Medicina Básica | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Noncytotoxic differentiation treatment of renal cell cancer | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.26e4b94f-724d-4d4c-8099-cdfc3ac846b7_B.pdf
- Tamaño:
- 1.92 MB
- Formato:
- Adobe Portable Document Format
- Descripción: